rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EOLS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Evolus: The Toxin-Plus-Filler Platform Is Working, But Priced In (Initiating Hold)
      Nov 17Seeking AlphaEOLS
      Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 13Yahoo FinanceEOLS
      Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ...

      Evolus Inc (EOLS) reaffirmed full-year revenue guidance of $330 million to $337 million while trimming operating expense outlook and advancing its injectable pipeline toward three launches by 2030.

      Nov 5Yahoo FinanceEOLS
      What Evolus (EOLS) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceEOLS
      Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceEOLS
      Evolus Q3 2026 Earnings Call Transcript
      Nov 4BenzingaEOLS
      Evolus to Participate in Upcoming Investor Conferences in New York and London
      Oct 28Yahoo FinanceEOLS
      Evolus to Report Third Quarter Financial Results on November 4, 2026
      Oct 21Yahoo FinanceEOLS
      Evolus Signs Option Agreement With Company Developing Injectable Treatment for Hair Restoration
      Oct 14Yahoo FinanceEOLS
      Evolus enters option deal for hair restoration treatment
      Oct 14Investing.comEOLS
      Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
      Oct 14Yahoo FinanceEOLS
      Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug - Evolus (NASDAQ:EOLS)

      The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.

      Oct 2BenzingaEOLS
      FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action

      The FDA objected to claims suggesting Jeuveau could make frown lines gone, deliver complete results, and begin working within two days.

      Oct 2Yahoo FinanceEOLS
      Evolus gets FDA warnings over Jeuveau IG post (EOLS:NASDAQ)
      Oct 2Seeking AlphaEOLS
      Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
      Oct 1Yahoo FinanceEOLS
      Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future

      On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of […]

      Sep 9Yahoo FinanceEOLS
      Evolus president & CEO David Moatazedi sells $950,018 in shares
      Sep 5Investing.comEOLS
      Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

      The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

      Aug 27Yahoo FinanceEOLS

      This is the newest page. Registered accounts read further back.